BOSTON — After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented at ...

Primary biliary cholangitis (PBC) is a rare liver disease. It blocks and destroys bile ducts in the liver. Doctors used to call it “primary biliary cirrhosis.” “Biliary” means bile. That ...

Medically reviewed by Jay N. Yepuri, MD Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the ...

Pruritus, or itching, is a common symptom of Primary Biliary Cholangitis (PBC). Learn more about its impact and the importance of raising awareness about this condition.

Linerixibat induced a dose-dependent reduction in itch among patients with primary biliary cholangitis-associated pruritus, according to results published in Clinical Gastroenterology and Hepatology.

Iqirvo (elafibranor) is a medicine that can help treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.

In one study involving 770 people with PBC, 61% of people had no symptoms at the time of diagnosis. In these cases, doctors typically detect PBC based on the presence of liver enzyme abnormalities ...

Seladelpar, and the dual PPAR-α and PPAR-δ agonist elafibranor, are an "unequivocal sign of progress, marking the arrival of a new era in which PBC treatment is expected to provide both ...

Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis (PBC) patients without cirrhosis, the FDA said in a safety communication ...

In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary biliary cholangitis (PBC). In the past years, numerous clinical studies have ...

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid ...

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) for treating primary biliary cholangitis (PBC). The analysis revealed ...